IBT B — Infant Bacterial Therapeutics AB Share Price
0.000.00%
Last trade - 00:00- SEK1.18bn
- SEK853.73m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.88 | ||
| Price to Tang. Book | 4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.11% | ||
| Return on Equity | -38.65% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Directors
- Peter Rothschild CHM (71)
- Staffan Stromberg CEO (54)
- Daniel Mackey CFO (47)
- Anders Kronstrom COO (54)
- Eamonn Connolly VRD (64)
- Jonas Rastad OTH (71)
- Margareta Hagman IND (55)
- Eva Iden IND (55)
- Anthon Jahreskog IND (41)
- Robert Molander IND (56)
- Kristina Sjoblom Nygren IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 30th, 2011
- Public Since
- March 29th, 2016
- No. of Employees
- 8
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 13,471,420
- Address
- Bryggargatan 10, STOCKHOLM, 111 21
- Web
- https://ibtherapeutics.com/
- Phone
- +46 841014555
- Auditors
- Deloitte AB
Upcoming Events for IBT B
Infant Bacterial Therapeutics AB Annual Shareholders Meeting
Q2 2024 Infant Bacterial Therapeutics AB Earnings Release
Similar to IBT B
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
What is the Infant Bacterial Therapeutics AB share price?
As of Today at 19:11 UTC, shares in Infant Bacterial Therapeutics AB are trading at SEK87.80. This share price information is delayed by 15 minutes.
How has the Infant Bacterial Therapeutics AB share price performed this year?
Shares in Infant Bacterial Therapeutics AB last closed at SEK87.80 and the price had moved by +75.95% over the past 365 days. In terms of relative price strength the Infant Bacterial Therapeutics AB share price has outperformed the FTSE Global All Cap Index by +61.19% over the past year.
What are the analyst and broker recommendations for Infant Bacterial Therapeutics AB?
The overall consensus recommendation for Infant Bacterial Therapeutics AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Infant Bacterial Therapeutics AB dividend yield?
Infant Bacterial Therapeutics AB does not currently pay a dividend.
Does Infant Bacterial Therapeutics AB pay a dividend?
Infant Bacterial Therapeutics AB does not currently pay a dividend.
When does Infant Bacterial Therapeutics AB next pay dividends?
Infant Bacterial Therapeutics AB does not currently pay a dividend.
How do I buy Infant Bacterial Therapeutics AB shares?
To buy shares in Infant Bacterial Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Infant Bacterial Therapeutics AB?
As of the previous close price of SEK87.80, shares in Infant Bacterial Therapeutics AB had a market capitalisation of SEK1.18bn.
Where are Infant Bacterial Therapeutics AB shares listed?
Here are the trading details for Infant Bacterial Therapeutics AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: IBT B
What kind of share is Infant Bacterial Therapeutics AB?
Based on an overall assessment of its quality, value and momentum Infant Bacterial Therapeutics AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Infant Bacterial Therapeutics AB share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Infant Bacterial Therapeutics AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Infant Bacterial Therapeutics AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -11.82%.
As of the last closing price of SEK87.80, shares in Infant Bacterial Therapeutics AB were trading +0.36% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Infant Bacterial Therapeutics AB PE Ratio?
The Infant Bacterial Therapeutics AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK87.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Infant Bacterial Therapeutics AB?
Infant Bacterial Therapeutics AB's management team is headed by:
- Peter Rothschild - CHM
- Staffan Stromberg - CEO
- Daniel Mackey - CFO
- Anders Kronstrom - COO
- Eamonn Connolly - VRD
- Jonas Rastad - OTH
- Margareta Hagman - IND
- Eva Iden - IND
- Anthon Jahreskog - IND
- Robert Molander - IND
- Kristina Sjoblom Nygren - IND